Core F: Biomarker/Neuroimaging Core
核心 F:生物标志物/神经影像核心
基本信息
- 批准号:10264499
- 负责人:
- 金额:$ 31.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAncillary StudyAreaAutopsyBiological MarkersBlood VesselsBrainCharacteristicsChemicalsClassificationClinicalClinical assessmentsCognitiveCognitive agingCollaborationsCollectionDataData CollectionDatabasesDementiaDevelopmentElderlyEnrollmentExerciseFundingGoalsHealthImpaired cognitionInterdisciplinary StudyLeadershipLinkMagnetic Resonance ImagingMentorsMotorNerve DegenerationOnline SystemsOutcomeOutputParticipantPersonsPilot ProjectsPositron-Emission TomographyProcessProtocols documentationReportingResearchResearch PersonnelResearch Project GrantsResearch SupportResource SharingResourcesRisk FactorsRoleStandardizationStructureValidationage relatedbasecomputerized data processingdata acquisitiondata hubdata managementdata sharingeducation researchhealth disparityin vivomild cognitive impairmentminority healthmultimodalityneuroimagingneuroimaging markerneuropathologynormal agingnovelnovel markerperipheral bloodracial and ethnic disparitiesretinal imagingspecific biomarkerstool
项目摘要
ABSTRACT – BIOMARKER/NEUROIMAGING CORE
The overall goal of the proposed Biomarker/Neuroimaging Core in the Rush Alzheimer’s Disease Research
Center (Rush ADRC) is to build a resource of neuroimaging data on participants of the Rush ADRC and
ancillary studies, and provide neuroimaging expertise to facilitate high quality, cutting edge, externally funded
research focusing on the transition from normal aging to mild cognitive impairment (MCI) to the earliest stages
of Alzheimer’s disease (AD) and other dementias. Specifically, the Biomarker/Neuroimaging Core will integrate
high quality, multi-modal, longitudinal in-vivo and ex-vivo brain magnetic resonance imaging (MRI) data and
newly collected positron emission tomography (PET) data from participants of the Rush ADRC and separately
funded studies, all based on state-of-the-art, uniform data acquisition protocols. The Biomarker/Neuroimaging
Core will perform thorough quality checks and detailed processing of the in-vivo and ex-vivo MRI data in the
database to generate rich output on macro-structural, micro-structural, chemical, and functional brain
characteristics and on novel classifiers of vascular and neurodegenerative processes in the older adult brain.
Quality checks and processing of the PET data will be conducted by SCAN (Standardized Centralized
Alzheimer’s and Related Dementias Neuroimaging). The Biomarker/Neuroimaging Core of the Rush ADRC will
widely distribute all brain MRI and PET data and processing results to investigators within and outside of the
Rush ADRC, and will provide neuroimaging expertise in support of research efforts in normal aging, cognitive
decline, mild cognitive impairment, AD and related dementias. The proposed Biomarker/Neuroimaging Core
will build upon strengths of the Rush ADRC including A) longitudinal clinical assessment of persons who enroll
without dementia, B) longitudinal ante-mortem biofluid collection, and C) post-mortem biospecimen collection
from large numbers of persons, many without dementia. The contributions of the Biomarker/Neuroimaging
Core will stimulate research that A) develops novel MRI-based classifiers of age-related neuropathologies, B)
elucidates brain mechanisms supporting cognitive and motor health or leading to decline, C) evaluates the
effects of risk factors on the brain, D) links neuroimaging to multi-level omics, E) supports the development and
validation of novel biomarkers based on peripheral blood and retinal imaging, and F) ascertains the role of
various brain characteristics in racial/ethnic disparities of cognitive aging related outcomes.
生物标志物/神经成像核心
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Konstantinos Arfanakis其他文献
Konstantinos Arfanakis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Konstantinos Arfanakis', 18)}}的其他基金
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementia
不同社区无痴呆老年人脑小血管疾病生物标志物的纵向验证
- 批准号:
10608782 - 财政年份:2021
- 资助金额:
$ 31.4万 - 项目类别:
In-vivo MRI-based prediction of TDP43 pathology in aging
基于体内 MRI 的 TDP43 衰老病理学预测
- 批准号:
10390407 - 财政年份:2019
- 资助金额:
$ 31.4万 - 项目类别:
In-vivo MRI-based prediction of TDP43 pathology in aging
基于体内 MRI 的 TDP43 衰老病理学预测
- 批准号:
10179293 - 财政年份:2019
- 资助金额:
$ 31.4万 - 项目类别:
In-vivo MRI-based prediction of TDP43 pathology in aging
基于体内 MRI 的 TDP43 衰老病理学预测
- 批准号:
10625261 - 财政年份:2019
- 资助金额:
$ 31.4万 - 项目类别:
Multimodal MRI biomarkers of small vessel disease for older persons with and without dementia.
患有或不患有痴呆症的老年人小血管疾病的多模态 MRI 生物标志物。
- 批准号:
9356352 - 财政年份:2016
- 资助金额:
$ 31.4万 - 项目类别:
Multimodal MRI biomarkers of small vessel disease for older persons with and without dementia.
患有或不患有痴呆症的老年人小血管疾病的多模态 MRI 生物标志物。
- 批准号:
9768245 - 财政年份:2016
- 资助金额:
$ 31.4万 - 项目类别:
Comprehensive Longitudinal Probabilistic Atlas of the Brain of Older Adults Without Dementia
无痴呆老年人大脑的综合纵向概率图谱
- 批准号:
9186870 - 财政年份:2016
- 资助金额:
$ 31.4万 - 项目类别:
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementia
不同社区无痴呆老年人脑小血管疾病生物标志物的纵向验证
- 批准号:
10369205 - 财政年份:2016
- 资助金额:
$ 31.4万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 31.4万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 31.4万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 31.4万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 31.4万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 31.4万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 31.4万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 31.4万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 31.4万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 31.4万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 31.4万 - 项目类别:














{{item.name}}会员




